We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Authorised psychiatrists can access products containing 3,4‑methylenedioxy‑methamphetamine (MDMA) or psilocybine for specific mental health conditions from 1 July 2023.
MDMA can be used for the treatment of post-traumatic stress disorder.
Psilocybine can be used for treatment-resistant depression.
To access products containing MDMA or psilocybine, you must be a registered psychiatrist approved under the TGA's Authorised Prescriber scheme.